V Craig Jordan

List of Publications by Year
in descending order

185	16,491	30551	17373
papers	citations	56 h-index	126 g-index

193	193	193	12170
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer. Molecular Cancer Research, 2022, 20, 193-201.	1.5	13
2	â€œIf I wanted to buy your brain, what would that cost?â€• rebirth at M.D. Anderson Cancer Center. , 2022, , 187-194.		0
3	Closing the circle on Tamoxifen Tales. , 2022, , 171-186.		0
4	South to Northwestern in Chicago. , 2022, , 131-154.		0
5	Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer. Frontiers in Endocrinology, 2022, 13, 869562.	1.5	3
6	Estrogen for the Treatment and Prevention of Breast Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 163-168.	1.0	2
7	50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?. Endocrine-Related Cancer, 2021, 28, R11-R30.	1.6	25
8	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast Cancer Research and Treatment, 2021, 190, 19-38.	1.1	6
9	Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative. Cancer Prevention Research, 2020, 13, 807-816.	0.7	17
10	Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Pharmacology, 2020, 98, 364-381.	1.0	17
11	The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Molecular Pharmacology, 2020, 98, 24-37.	1.0	19
12	Serendipity in the search for â€œmorning-after pillsâ€•led to clomiphene for the induction of ovulation. F&S Science, 2020, 1, 3-13.	0.5	0
13	The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Annals of Surgical Oncology, 2019, 26, 1981-1990.	0.7	11
14	A Novel Strategy to Improve Womenâ€™s Health: Selective Estrogen Receptor Modulators. Cancer Drug Discovery and Development, 2019, , 189-213.	0.2	5
15	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
16	Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clinical Cancer Research, 2018, 24, 3480-3482.	3.2	8
17	Steroid Receptors in Breast Cancer. , 2018, , 272-281.e2.		2
18	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R83-R113.	1.6	21

#	Article	IF	Citations
19	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Womenâ€™s Health. Endocrinology, 2018, 159, 2980-2990.	1.4	17
20	Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Molecular Pharmacology, 2018, 94, 812-822.	1.0	24
21	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. Expert Review of Anticancer Therapy, 2017, 17, 297-310.	1.1	3
22	ER. , 2017, , 997-1006.		0
23	The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice. Cancer Prevention Research, 2017, 10, 219-222.	0.7	2
24	Celebrating an illustrious career in breast cancer research, SERMS and mentorship. Breast Cancer Management, 2017, 6, 83-87.	0.2	2
25	Endoxifen: The End, or Are We at the Beginning?. Journal of Clinical Oncology, 2017, 35, 3378-3379.	0.8	6
26	The modulation of estrogen-induced apoptosis as an interpretation of the womenâ€™s health initiative trials. Expert Review of Endocrinology and Metabolism, 2016, 11, 81-86.	1.2	10
27	Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?. , 2016, , 83-101.		0
28	Cancer chemoprevention at the crossroads?. Breast Cancer Management, 2015, 4, 285-288.	0.2	0
29	Oral pure antiestrogens as a solution to acquired drug resistance to aromatase inhibitors. Breast Cancer Management, 2015, 4, 275-277.	0.2	0
30	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocrine-Related Cancer, 2015, 22, R1-R31.	1.6	111
31	The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Molecular and Cellular Endocrinology, 2015, 418, 245-263.	1.6	27
32	Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. British Journal of Clinical Pharmacology, 2015, 79, 254-267.	1.1	11
33	Estrogen Receptor Mutations Found in Breast Cancer Metastases Integrated With the Molecular Pharmacology of Selective ER Modulators. Journal of the National Cancer Institute, 2015, 107, djv075.	3.0	35
34	ER. , 2015, , 1-10.		0
35	Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 101-114.	0.1	0
36	Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients. Journal of the National Cancer Institute, 2014, 106, .	3.0	17

#	Article	IF	Citations
37	Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. Journal of the National Cancer Institute, 2014, 106, dju296-dju296.	3.0	34
38	Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocrine-Related Cancer, 2014, 21, R235-R246.	1.6	128
39	A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis?. Menopause, 2014, 21, 1160-1164.	0.8	10
40	The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids, 2014, 90, 3-12.	0.8	22
41	Selective estrogen-induced apoptosis in breast cancer. Steroids, 2014, 90, 60-70.	0.8	11
42	Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Steroids, 2014, 90, 44-52.	0.8	30
43	Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. European Journal of Cancer, 2014, 50, 2877-2886.	1.3	15
44	Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving. Breast Cancer Management, 2014, 3, 321-326.	0.2	4
45	Any surprises from selective oestrogen-receptor modulators?. Nature Reviews Clinical Oncology, 2013, 10, 432-434.	12.5	0
46	Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. Vitamins and Hormones, 2013, 93, 1-49.	0.7	13
47	NOVEL SELECTIVE ESTROGEN RECEPTOR MODULATORS. , 2013, , 325-359.		0
48	ENDOCRINE PREVENTION OF BREAST CANCER. , 2013, , 361-390.		0
49	Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause, 2013, 20, 372-382.	0.8	34
50	The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice. Current Clinical Pharmacology, 2013, 8, 135-155.	0.2	297
51	Chemoprevention: Cinderella Waiting for the Ball. Milestones in Drug Therapy, 2013, , 115-134.	0.1	1
52	Metabolites of Tamoxifen as the Basis of Drug Development. Milestones in Drug Therapy, 2013, , 47-67.	0.1	0
53	Acquired Resistance to Tamoxifen: Back to the Beginning. Milestones in Drug Therapy, 2013, , 143-163.	0.1	0
54	Adjuvant Therapy: The Breakthrough. Milestones in Drug Therapy, 2013, , 69-84.	0.1	1

#	Article	IF	Citations
55	The Wisconsin Story in the 1980s: Discovery of Target Site-Specific Estrogen Action. Milestones in Drug Therapy, 2013, , 85-99.	0.1	0
56	Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens. Milestones in Drug Therapy, 2013, , 1-30.	0.1	0
57	Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Hormone Molecular Biology and Clinical Investigation, 2012, 9, 143-163.	0.3	62
58	Adapting to change and seeing the opportunities in breast cancer management. Breast Cancer Management, 2012, 1, 1-3.	0.2	0
59	Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas, 2011, 70, 315-321.	1.0	56
60	Four decades of discovery in breast cancer research and treatment an interview with V. Craig Jordan. International Journal of Developmental Biology, 2011, 55, 703-712.	0.3	15
61	Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A â€œNewâ€•Biology of Estrogen-induced Apoptosis. Cancer Prevention Research, 2011, 4, 633-637.	0.7	59
62	The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast, 2011, 20, S1-S11.	0.9	23
63	Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18879-18886.	3.3	151
64	Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opinion on Pharmacotherapy, 2011, 12, 657-674.	0.9	23
65	Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: A unifying concept in anti-hormone resistance. International Journal of Oncology, 2010, 37, 387-98.	1.4	18
66	Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Hormone Molecular Biology and Clinical Investigation, 2010, 2, 235-243.	0.3	58
67	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research, 2010, 3, 696-706.	0.7	560
68	Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 481-499.	0.9	111
69	A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention. Cancer Research, 2009, 69, 1243-1254.	0.4	91
70	New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast, 2009, 18, S10-S17.	0.9	19
71	Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The â€˜personalisedâ€™ approach?. European Journal of Cancer, 2009, 45, 2274-2283.	1.3	61
72	Early breast cancer. Lancet, The, 2009, 373, 1463-1479.	6.3	214

#	Article	IF	Citations
73	The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Current Signal Transduction Therapy, 2009, 4, 88-102.	0.3	24
74	Breast-Cancer Prevention with Antiestrogens. , 2009, , 213-231.		0
75	Recent Progress in Breast Cancer Research. , 2009, , 385-408.		2
76	Drug Resistance to Antiestrogens. , 2009, , 47-68.		0
77	Low-Dose Estrogen Therapy to Reverse Acquired Antihormonal Resistance in the Treatment of Breast Cancer. Clinical Breast Cancer, 2008, 8, 124-133.	1.1	21
78	Estrogen Receptor Pathways and Breast Cancer. , 2008, , 189-206.		2
79	Tamoxifen: Catalyst for the change to targeted therapy. European Journal of Cancer, 2008, 44, 30-38.	1.3	174
80	By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy. Breast Cancer Research, 2008, 10, S16.	2.2	3
81	The Rise of Raloxifene and the Fall of Invasive Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 831-833.	3.0	11
82	The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancerâ€"Survival or Death?. Journal of Clinical Oncology, 2008, 26, 3073-3082.	0.8	98
83	Selective Estrogen Receptor Modulators and Phytoestrogens. Planta Medica, 2008, 74, 1656-1665.	0.7	179
84	Selective Estrogen Modulators as an Anticancer Tool:. Advances in Experimental Medicine and Biology, 2008, 630, 206-219.	0.8	48
85	A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?. , 2008, , 391-398.		0
86	Problems With the Progesterone Receptor in Practice?. Journal of Clinical Oncology, 2007, 25, 1957-1959.	0.8	10
87	SERMs: Meeting the Promise of Multifunctional Medicines. Journal of the National Cancer Institute, 2007, 99, 350-356.	3.0	104
88	Estrogen Receptors in BRCA1-Mutant Breast Cancer: Now You See Them, Now You Don't. Journal of the National Cancer Institute, 2007, 99, 1655-1657.	3.0	2
89	Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2207-2209.	1.1	16
90	Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics, 2007, 6, 2817-2827.	1.9	58

#	Article	IF	Citations
91	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 2007, 72, 7-25.	0.8	282
92	New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids, 2007, 72, 829-842.	0.8	147
93	Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5815-5824.	0.8	285
94	Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer, 2007, 7, 46-53.	12.8	198
95	Oestrogen is bad for patients with breast cancer?. Breast Cancer Research, 2007, 9, .	2.2	1
96	The current status of breast cancer chemoprevention: A star is born. Journal of Surgical Oncology, 2007, 95, 4-5.	0.8	5
97	Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast, 2007, 16, 105-113.	0.9	20
98	Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer, 2007, 14, 113-122.	1.3	26
99	SERMs for the treatment and prevention of breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 229-239.	2.6	72
100	Activated Estrogens and Antiestrogens: A 30-Year Journey with David Kupfer. Drug Metabolism Reviews, 2006, 38, 117-127.	1.5	3
101	International Union of Pharmacology. LXIV. Estrogen Receptors. Pharmacological Reviews, 2006, 58, 773-781.	7.1	492
102	Optimising endocrine approaches for the chemoprevention of breast cancer. European Journal of Cancer, 2006, 42, 2909-2913.	1.3	40
103	Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. Journal of Steroid Biochemistry and Molecular Biology, 2006, 102, 128-138.	1.2	18
104	Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology, 2006, 147, S269-S276.	2.7	254
105	3-Methylcholanthrene and Other Aryl Hydrocarbon Receptor Agonists Directly Activate Estrogen Receptor Î±. Cancer Research, 2006, 66, 2459-2467.	0.4	120
106	The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice. Clinical Cancer Research, 2006, 12, 5010-5013.	3.2	51
107	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 2727.	3.8	1,499
108	Pak up Your Breast Tumorâ€"and Grow!. Journal of the National Cancer Institute, 2006, 98, 657-659.	3.0	8

#	Article	IF	Citations
109	Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. Journal of Endocrinology, 2006, 191, 599-604.	1.2	6
110	Prevention of Breast Cancer. , 2006, , 63-94.		0
111	The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast, 2005, 14, 624-630.	0.9	48
112	Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 591, 247-263.	0.4	227
113	Chemoprevention in the 21st Century: Is a Balance Best or Should Women Have No Estrogen at All?. Journal of Clinical Oncology, 2005, 23, 1598-1600.	0.8	3
114	The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death. Experimental Biology and Medicine, 2004, 229, 722-731.	1.1	25
115	SERMS (Selective Estrogen Receptor Modulators). , 2004, , 221-228.		0
116	Selective estrogen receptor modulation. Cancer Cell, 2004, 5, 207-213.	7.7	307
117	The biological role of estrogen receptors Î± and Î² in cancer. Critical Reviews in Oncology/Hematology, 2004, 50, 3-22.	2.0	262
118	Aromatase inhibitors that regulate estrogen target tissues selectively?. Bone, 2004, 34, 372-375.	1.4	3
119	Estrogen Action and Breast Cancer. , 2004, , 317-358.		1
120	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. Part 2. Clinical Considerations and New Agents. ChemInform, 2003, 34, no.	0.1	0
121	Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2003, 2, 205-213.	21.5	676
122	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents. Journal of Medicinal Chemistry, 2003, 46, 1081-1111.	2.9	392
123	Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions. Journal of Medicinal Chemistry, 2003, 46, 883-908.	2.9	396
124	Robertson JFR, Nicholson RI, Hayes DF:Endocrine Therapy of Breast Cancer. London, UK: Martin Dunitz; 2002. 296pp.. Breast Cancer Research, 2003, 5, 1.	2.2	0
125	Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy. Breast Cancer Research, 2003, 5, 281-3.	2.2	1
126	The Ups and Downs of the Estrogen Receptor. Journal of Clinical Oncology, 2003, 21, 3-4.	0.8	11

#	Article	IF	Citations
127	Modulation of Estrogen Receptor Î± Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12. Journal of Biological Chemistry, 2003, 278, 7630-7638.	1.6	53
128	Apoptotic Action of 17Â-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo. Journal of the National Cancer Institute, 2003, 95, 1586-1597.	3.0	140
129	Advances in endocrine therapy for the treatment and prevention of breast cancer. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 211-222.	0.5	2
130	The estrogen receptor: a model for molecular medicine. Clinical Cancer Research, 2003, 9, 1980-9.	3.2	317
131	Structure-Function Relationships of the Raloxifene-Estrogen Receptor-Î± Complex for Regulating Transforming Growth Factor-Î± Expression in Breast Cancer Cells. Journal of Biological Chemistry, 2002, 277, 9189-9198.	1.6	68
132	Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice. Journal of the National Cancer Institute, 2002, 94, 274-283.	3.0	65
133	Role of antiestrogens and aromatase inhibitors in breast cancer treatment. Current Opinion in Obstetrics and Gynecology, 2002, 14, 5-12.	0.9	11
134	Selective Estrogen Receptor Modulators as a New Therapeutic Drug Group: Concept to Reality in a Decade. Clinical Breast Cancer, 2002, 2, 272-281.	1.1	31
135	A new day dawns: women without oestrogen or is a balance best?. Breast Cancer Research, 2002, 4, 218-21.	2.2	2
136	The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncology, The, 2002, 3, 207-214.	5.1	105
137	Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends in Molecular Medicine, 2002, 8, 82-88.	3.5	114
138	Chemoprevention of Breast Cancer: A Model for Change. Journal of Clinical Oncology, 2002, 20, 1-3.	0.8	364
139	The secrets of selective estrogen receptor modulation: Cell-specific coregulation. Cancer Cell, 2002, 1, 215-217.	7.7	23
140	Chemoprevention of breast cancer: current and future prospects. Cancer and Metastasis Reviews, 2002, 21, 311-321.	2.7	18
141	Molecular Mechanism of Action at Estrogen Receptor Î± of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen**This work was supported by NIH CA-56143 (to V.C.J.); Fundacl§ao Coordenacl§ao de Aperfeicl§oamento de Pessoal de Nìvel Superior, (CAPES) Scholarship, Brazil (to R.D.); the U.S. Army Medical Research and Material Command Breast Cancer Research Program, DAMD17â€“96-16169 (to H.L.); the generosity of the Lynn Sage Breast Cancer Research Foundation of Northwestern Memorial Hospital; and the. Endocrinology, 2001, 142, 838-846.	1.4	84
142	New strategies for the treatment of breast cancer. Breast Cancer, 2001, 8, 265-274.	1.3	0
143	Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment, 2001, 65, 125-134.	1.1	629
144	Estrogen, Selective Estrogen Receptor Modulation, and Coronary Heart Disease: Something or Nothing. Journal of the National Cancer Institute, 2001, 93, 2-4.	3.0	20

#	Article	IF	Citations
145	Raloxifene for the treatment and prevention of breast cancer?. Expert Review of Anticancer Therapy, 2001, 1, 334-340.	1.1	10
146	The Past, Present, and Future of Selective Estrogen Receptor Modulation. Annals of the New York Academy of Sciences, 2001, 949, 72-79.	1.8	47
147	Chemoprevention of Breast Cancer. Cancer Treatment and Research, 2001, 106, 137-154.	0.2	3
148	Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman. Annals of Surgical Oncology, 2000, 7, 67-71.	0.7	6
149	Tamoxifen: a personal retrospective. Lancet Oncology, The, 2000, 1, 43-49.	5.1	39
150	Tamoxifen and Other Antiestrogens in Prevention and Therapy of Breast Cancer. , 2000, , 79-99.		0
151	Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*. Endocrine Reviews, 1999, 20, 253-278.	8.9	206
152	The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1999, 281, 2189.	3.8	1,661
153	The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. Journal of Mammary Gland Biology and Neoplasia, 1999, 4, 401-413.	1.0	8
154	Current controversies in breast cancer management. Current Problems in Surgery, 1999, 36, 153-216.	0.6	9
155	Development of a New Prevention Maintenance Therapy for Postmenopausal Women. Recent Results in Cancer Research, 1999, 151, 96-109.	1.8	5
156	Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer. , 1999, , 283-311.		1
157	Designer Estrogens. Scientific American, 1998, 279, 60-67.	1.0	90
158	Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen. Breast Cancer, 1998, 5, 99-106.	1.3	9
159	Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow. Journal of the National Cancer Institute, 1998, 90, 967-971.	3.0	78
160	Questions about Tamoxifen and the Future Use of Antiestrogens. Oncologist, 1998, 3, 104-110.	1.9	13
161	Targeted anti-estrogens to treat and prevent diseases in women. Trends in Molecular Medicine, 1996, 2, 218-223.	2.6	28
162	Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?. , 1996, 12, 339-345.		4

#	Article	IF	Citations
163	Molecular, Cellular, and Systemic Mechanisms of Antiestrogen Action. , 1996, , 307-355.		0
164	Alternate antiestrogens and approaches to the prevention of breast cancer. Journal of Cellular Biochemistry, 1995, 59, 51-57.	1.2	29
165	?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancer. Breast Cancer Research and Treatment, 1995, 36, 267-285.	1.1	140
166	An Overview of Considerations for the Testing of Tamoxifen as a Preventive for Breast Cancer. Annals of the New York Academy of Sciences, 1995, 768, 141-147.	1.8	14
167	Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Research and Treatment, 1994, 31, 11-25.	1.1	55
168	What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Research and Treatment, 1994, 31, 27-39.	1.1	43
169	Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Research and Treatment, 1994, 31, 41-52.	1.1	110
170	Drug Resistance to Antioestrogen Therapy. , 1994, , 61-68.		0
171	An appraisal of strategies to reduce the incidence of breast cancer. Stem Cells, 1993, 11, 252-262.	1.4	14
172	A current view of tamoxifen for the treatment and prevention of breast cancer. British Journal of Pharmacology, 1993, 110, 507-517.	2.7	252
173	A Risk-Benefit Assessment of Tamoxifen Therapy. Drug Safety, 1993, 8, 381-397.	1.4	56
174	Investigation of the Mechanism of Tamoxifen-Stimulated Breast Tumor Growth With Nonisomerizable Analogues of Tamoxifen and Metabolites. Journal of the National Cancer Institute, 1993, 85, 806-812.	3.0	89
175	Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer. New England Journal of Medicine, 1992, 326, 852-856.	13.9	1,089
176	Suppression of Mouse Mammary Tumorigenesis by Long-Term Tamoxifen Therapy. Journal of the National Cancer Institute, 1991, 83, 492-496.	3.0	136
177	Regulation of Prolactin Synthesis in Vitro by Estrogenic and Antiestrogenic Derivatives of Estradiol and Estrone*. Endocrinology, 1989, 124, 1717-1726.	1.4	38
178	Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. European Journal of Cancer & Clinical Oncology, 1989, 25, 1777-1788.	0.9	43
179	The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Research and Treatment, 1988, 11, 197-209.	1.1	122
180	Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Research and Treatment, 1988, 12, 297-302.	1.1	158

#	Article	IF	Citations
181	Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. European Journal of Cancer & Clinical Oncology, 1988, 24, 1817-1821.	0.9	47
182	Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment, 1987, 10, 31-35.	1.1	331
183	Inhibition of the Uterotropic Activity of Estrogens and Antiestrogens by the Short Acting Antiestrogen LY117018*. Endocrinology, 1983, 113, 463-468.	1.4	76
184	Nonsteroidal antiestrogens: Their biological effects and potential mechanisms of action. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1978, 4, 363-390.	1.1	114
185	Anti-estrogens and selective estrogen-receptor modulators. , 0, , 884-892.		0